newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approxima